Methoxy Polyethylene Glycol-Epoetin Beta Once A Month Versus Darbepoetin Alfa Once A Week for Treatment of Anemia in Hemodialysis Patients: A Randomized, Multicenter, Open-label Trial
Not Applicable
- Conditions
- Hemodialysis patients with renal anemia
- Registration Number
- JPRN-UMIN000008073
- Lead Sponsor
- Blood Purification Center, Mie University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
Hemodialysis vintage less than 6 months Inpatient Patient who received transfusion within six months Anemic patient who has another cause of renal anemia like hematological or gastrointestinal diseases Patient who has poor prognostic malignancy Patient who can not agree with the study Patient who was judged inadequate case for the study by doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency that hemoglobin level becomes less than 10g/dl for six months evaluation period (12 times of observation).
- Secondary Outcome Measures
Name Time Method Frequency that hemoglobin level becomes out of target range (10-12g/dl) for six months evaluation period . Frequency that hemoglobin level becomes over 12g/dl for six months evaluation period. Average value and coefficient of variance of hemoglobin for six months evaluation period. Frequency that hemoglobin level becomes less than 10g/dl for 12 months study period. Frequency that hemoglobin level becomes out of target range (10-12g/dl) for 12 months study period . Complications (death, new onset of cardiovasculr disease, and vascular access failure)